Internal Medicine, Hematology & Oncology · Cerritos, CA
NPI
1972766772
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
18000 Studebaker Rd Ste 800
Cerritos, CA, 90703
Phone (562) 735-3226
Groups this clinician bills Medicare through
Medicare paid, 2024
$553K
35,044 services
Medicare patients, 2024
109
Average age 71
Drug cost, 2024
$6.8M
1,460 prescriptions
Company payments, 2025
$2,927
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Foluso N Ogunleye was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 704 times for 18 patients. In total Foluso N Ogunleye billed 35,044 services in 69 codes, and Medicare paid $553K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 704 | 18 | $0.09 | $61.87 |
| 99214 Office E&M - Established | Office | 116 | 51 | $87.41 | $10K |
| 96367 Intravenous Infusion, Hydration | Office | 106 | 19 | $21.87 | $2,318 |
| 96365 Intravenous Infusion, Hydration | Office | 57 | 25 | $43.56 | $2,483 |
| 96372 Injection Administration | Office | 57 | 14 | $9.99 | $569 |
| 96413 Chemotherapy Administration | Office | 55 | 19 | $95.07 | $5,229 |
| 99213 Office E&M - Established | Office | 42 | 34 | $63.03 | $2,647 |
| 85025 Blood Count | Office | 41 | 14 | $7.61 | $312 |
| 99204 Office E&M - New | Office | 13 | 13 | $121.97 | $1,586 |
By year: 2022 $383K for 41,199 services; 2023 $425K for 42,697 services; 2024 $553K for 35,044 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 41 | 14 | $7.61 | $312 |
Medicare prescription drug claims, 2024
In 2024, the drug Foluso N Ogunleye prescribed most often to Medicare patients was Letrozole, with 179 prescriptions and refills. In total Foluso N Ogunleye wrote 1,460 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 179 | 454 | 58 | $3,697 |
| Erleada Apalutamide | 122 | 124 | 11 | $2.0M |
| Gabapentin Generic | 72 | 80 | 11 | $614 |
| Famotidine Generic | 71 | 149 | 31 | $889 |
| Anastrozole Generic | 68 | 182 | 23 | $836 |
| Dexamethasone Generic | 54 | 92 | 22 | $996 |
| Prochlorperazine Maleate Generic | 54 | 54 | 26 | $520 |
| Revlimid Lenalidomide | 45 | 45 | Under 11 | $1.1M |
| Folic Acid Generic | 44 | 104 | 14 | $494 |
| Ondansetron Odt Ondansetron | 44 | 44 | 22 | $644 |
| Hydroxyurea Generic | 41 | 85 | 20 | $1,113 |
| Tagrisso Osimertinib Mesylate | 39 | 39 | Under 11 | $727K |
| Eliquis Apixaban | 37 | 39 | 15 | $24K |
| Allopurinol Generic | 36 | 54 | 15 | $166 |
| Lenalidomide Generic | 28 | 28 | Under 11 | $415K |
Brand drugs: 452 claims; generic drugs: 1,008 claims; opioid claims: 47.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Foluso N Ogunleye $2,927 ($2,927 in general payments such as food, travel and fees) from 41 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $248.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 10 | $248 |
| Pfizer Inc. PFE | 10 | $236 |
| Janssen Biotech, Inc. JNJ | 10 | $227 |
| Celgene Corporation BMY | 10 | $196 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $173 |
| Geron Corporation GERN | 5 | $127 |
| Karyopharm Therapeutics Inc. KPTI | 4 | $121 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 4 | $105 |
| Incyte Corporation INCY | 5 | $102 |
| Seagen Inc. PFE | 1 | $99 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.